If one can circumvent the difficulty posed by the high concentration of sGSN in plasma, sGSN blockade in the TME could boost the antigenic visibility of tumor cells and, in conjunction with checkpoint blockade immunotherapy, help augment cancer control by CD8+ T cells. This evidence concerns the gene CD8A and cancer.